{"schema_version":"secwatch.filing_event.v1","accession":"0000784199-24-000234","form_type":"8-K","ticker":"AORT","cik":"0000784199","company_name":"ARTIVION, INC.","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.015461+00:00","generated_at":"2026-05-30T04:07:09.916610+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Artivion Q3 revenue $95.8M (+9% YoY); EBITDA $17.7M (+28%); guides FY $389-396M","bullets":["Revenue $95.8M (+9% GAAP, +10% constant currency); net loss ($2.3M) ($0.05 EPS) vs ($9.8M) ($0.24) prior year.","Non-GAAP net income $5.0M ($0.12 EPS) vs $0.7M ($0.02); includes $2.4M foreign currency gains.","Adjusted EBITDA $17.7M (+28%); FY guidance narrowed to $389-396M revenue and $69-72M EBITDA.","On-X +15%, BioGlue +14%, stent grafts +12%; APAC +23% and LatAm +21% (constant currency +32%).","Regulatory milestones: AMDS PMA module submitted, BioGlue approved in China, NEXUS TRIOMPHE enrollment complete."],"urls":{"canonical":"https://secwatch.observer/filing/0000784199-24-000234","json":"https://secwatch.observer/filing/0000784199-24-000234.json","markdown":"https://secwatch.observer/filing/0000784199-24-000234.md","text":"https://secwatch.observer/filing/0000784199-24-000234.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/784199/000078419924000234/0000784199-24-000234-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/784199/000078419924000234/aort-20241107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T04:07:09.916610+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}